UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 1.720

Sortiert nach

Inhibition of complement C1s improves severe hemolytic anemia in cold agglutinin disease: a first-in-human trial

Blood, 2019-02, Vol.133 (9), p.893-901

2019

Link zum Volltext

Verfügbarkeit prüfen

A Randomized, First‐in‐Human, Healthy Volunteer Trial of sutimlimab, a Humanized Antibody for the Specific Inhibition of the Classical Complement Pathway

Clinical pharmacology and therapeutics, 2018-10, Vol.104 (4), p.655-663

2018

Link zum Volltext

Verfügbarkeit prüfen

Specific Inhibition of the Classical Complement Pathway Prevents C3 Deposition along the Dermal-Epidermal Junction in Bullous Pemphigoid

Journal of investigative dermatology, 2019-12, Vol.139 (12), p.2417-2424.e2

2019

Link zum Volltext

Verfügbarkeit prüfen

The aptamer BT200 blocks von Willebrand factor and platelet function in blood of stroke patients

Scientific reports, 2021-02, Vol.11 (1), p.3092-3092, Article 3092

2021

Link zum Volltext

Verfügbarkeit prüfen

First-in-human evaluation of anti von Willebrand factor therapeutic aptamer ARC1779 in healthy volunteers

Circulation (New York, N.Y.), 2007-12, Vol.116 (23), p.2678-2686

2007

Link zum Volltext

Verfügbarkeit prüfen

Pharmacokinetics, pharmacodynamics and safety of aptamers

Advanced drug delivery reviews, 2018-09, Vol.134, p.36-50

2018

Link zum Volltext

Verfügbarkeit prüfen

Von Willebrand Factor in Cardiovascular Disease : Focus on Acute Coronary Syndromes

Circulation (New York, N.Y.), 2008-03, Vol.117 (11), p.1449-1459

2008

Link zum Volltext

Verfügbarkeit prüfen

The development and characterization of a long acting anti‐thrombotic von Willebrand factor (VWF) aptamer

Journal of thrombosis and haemostasis, 2020-05, Vol.18 (5), p.1113-1123

2020

Link zum Volltext

Verfügbarkeit prüfen

Anti–von Willebrand factor aptamer ARC1779 for refractory thrombotic thrombocytopenic purpura

Transfusion (Philadelphia, Pa.), 2009-10, Vol.49 (10), p.2181-2185

2009

Link zum Volltext

Verfügbarkeit prüfen

Recurrent pyloric stenosis: a form of the incomplete pyloromyotomy

Journal of pediatric surgery case reports, 2018-02, Vol.29 (C), p.14-17

2018

Link zum Volltext

Verfügbarkeit prüfen

The von Willebrand factor A-1 domain binding aptamer BT200 elevates plasma levels of von Willebrand factor and factor VIII: a first-in-human trial

Haematologica (Roma), 2022-09, Vol.107 (9), p.2121-2132

2022

Link zum Volltext

Verfügbarkeit prüfen

Potent and rapid reversal of the von Willebrand factor inhibitor aptamer BT200

Journal of thrombosis and haemostasis, 2020-07, Vol.18 (7), p.1695-1704

2020

Link zum Volltext

Verfügbarkeit prüfen

The von Willebrand factor–binding aptamer rondaptivon pegol as a treatment for severe and nonsevere hemophilia A

Blood, 2023-03, Vol.141 (10), p.1147-1158

2023

Link zum Volltext

Verfügbarkeit prüfen

The aptamer BT200 effectively inhibits von Willebrand factor (VWF) dependent platelet function after stimulated VWF release by desmopressin or endotoxin

Scientific reports, 2020-07, Vol.10 (1), p.11180-11180, Article 11180

2020

Link zum Volltext

Verfügbarkeit prüfen

Blockade of HLA Antibody-Triggered Classical Complement Activation in Sera From Subjects Dosed With the Anti-C1s Monoclonal Antibody TNT009-Results from a Randomized First-in-Human Phase 1 Trial

Transplantation, 2017-10, Vol.101 (10), p.2410

2017

Link zum Volltext

Verfügbarkeit prüfen

The anti-von Willebrand factor aptamer ARC1779 increases von Willebrand factor levels and platelet counts in patients with type 2B von Willebrand disease

Thrombosis and haemostasis, 2012-08, Vol.108 (2), p.284

2012

Link zum Volltext

Verfügbarkeit prüfen

A dose ranging phase I/II trial of the von Willebrand factor inhibiting aptamer ARC1779 in patients with congenital thrombotic thrombocytopenic purpura

Thrombosis and haemostasis, 2011-09, Vol.106 (3), p.539

2011

Link zum Volltext

Verfügbarkeit prüfen

A randomised pilot trial of the anti-von Willebrand factor aptamer ARC1779 in patients with type 2b von Willebrand disease

Thrombosis and haemostasis, 2010-09, Vol.104 (3), p.563

2010

Link zum Volltext

Verfügbarkeit prüfen

Inhibition of von Willebrand factor by ARC1779 in patients with acute thrombotic thrombocytopenic purpura

Thrombosis and haemostasis, 2011-03, Vol.105 (3), p.545

2011

Link zum Volltext

Verfügbarkeit prüfen

The VWF binding aptamer rondoraptivon pegol increases platelet counts and VWF/FVIII in type 2B von Willebrand disease

Blood advances, 2022-09, Vol.6 (18), p.5467-5476

2022

Link zum Volltext

Verfügbarkeit prüfen

Hospital- and patient-level characteristics and the risk of appendiceal rupture and negative appendectomy in children

JAMA : the journal of the American Medical Association, 2004-10, Vol.292 (16), p.1977

2004

Link zum Volltext

Verfügbarkeit prüfen

Initial experience from a double-blind, placebo-controlled, clinical outcome study of ARC1779 in patients with thrombotic thrombocytopenic purpura

American journal of hematology, 2012-04, Vol.87 (4), p.430-432

2012

Link zum Volltext

Verfügbarkeit prüfen

Evidence of persistent neurologic injury following thrombotic thrombocytopenic purpura

American journal of hematology, 2011-01, Vol.86 (1), p.87-89

2011

Link zum Volltext

Verfügbarkeit prüfen

The aptamer ARC1779 blocks von Willebrand factor-dependent platelet function in patients with thrombotic thrombocytopenic purpura ex vivo

Transfusion (Philadelphia, Pa.), 2010-05, Vol.50 (5), p.1079-1087

2010

Link zum Volltext

Verfügbarkeit prüfen

The aptamer ARC1779 is a potent and specific inhibitor of von willebrand factor mediated ex vivo platelet function in acute myocardial infarction

Platelets (Edinburgh), 2009-01, Vol.20 (5), p.334-340

2009

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 1.720

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(1.532)
Mit Volltextzugriff
(1.487)

Publikationsform

2 weitere anzeigen...

Weniger anzeigen...

Sprache

2 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Science & Technology
(1.133)
Life Sciences & Biomedicine
(925)
Humans
(775)
Male
(490)
Female
(465)
Biological And Medical Sciences
(346)
Middle Aged
(307)
Medical Sciences
(302)
Adult
(250)
Aged
(219)
Animals
(198)
Cardiovascular System & Cardiology
(190)
Surgery
(149)
Cardiac & Cardiovascular Systems
(139)
Physical Sciences
(123)
Risk Factors
(116)
Adolescent
(114)
Child
(101)
Science & Technology - Other Topics
(99)
Treatment Outcome
(91)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Journal Of The American College Of Cardiology
(44)
Journal Of Vascular Surgery
(39)
The New England Journal Of Medicine
(30)
Plos One
(27)
Nature
(19)
The Astrophysical Journal
(19)
Blood
(18)
Proceedings Of The National Academy Of Sciences - Pnas
(18)
Science
(18)
Circulation
(17)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

Menü

Weitere Dienste

Einstellungen

Inhibition of complement C1s improves severe hemolytic anemia in cold agglutinin disease: a first-in-human trial

A Randomized, First‐in‐Human, Healthy Volunteer Trial of sutimlimab, a Humanized Antibody for the Specific Inhibition of the Classical Complement Pathway

Specific Inhibition of the Classical Complement Pathway Prevents C3 Deposition along the Dermal-Epidermal Junction in Bullous Pemphigoid

The aptamer BT200 blocks von Willebrand factor and platelet function in blood of stroke patients

First-in-human evaluation of anti von Willebrand factor therapeutic aptamer ARC1779 in healthy volunteers

Pharmacokinetics, pharmacodynamics and safety of aptamers

Von Willebrand Factor in Cardiovascular Disease : Focus on Acute Coronary Syndromes

The development and characterization of a long acting anti‐thrombotic von Willebrand factor (VWF) aptamer

Anti–von Willebrand factor aptamer ARC1779 for refractory thrombotic thrombocytopenic purpura

Recurrent pyloric stenosis: a form of the incomplete pyloromyotomy

The von Willebrand factor A-1 domain binding aptamer BT200 elevates plasma levels of von Willebrand factor and factor VIII: a first-in-human trial

Potent and rapid reversal of the von Willebrand factor inhibitor aptamer BT200

The von Willebrand factor–binding aptamer rondaptivon pegol as a treatment for severe and nonsevere hemophilia A

The aptamer BT200 effectively inhibits von Willebrand factor (VWF) dependent platelet function after stimulated VWF release by desmopressin or endotoxin

Blockade of HLA Antibody-Triggered Classical Complement Activation in Sera From Subjects Dosed With the Anti-C1s Monoclonal Antibody TNT009-Results from a Randomized First-in-Human Phase 1 Trial

The anti-von Willebrand factor aptamer ARC1779 increases von Willebrand factor levels and platelet counts in patients with type 2B von Willebrand disease

A dose ranging phase I/II trial of the von Willebrand factor inhibiting aptamer ARC1779 in patients with congenital thrombotic thrombocytopenic purpura

A randomised pilot trial of the anti-von Willebrand factor aptamer ARC1779 in patients with type 2b von Willebrand disease

Inhibition of von Willebrand factor by ARC1779 in patients with acute thrombotic thrombocytopenic purpura

The VWF binding aptamer rondoraptivon pegol increases platelet counts and VWF/FVIII in type 2B von Willebrand disease

Hospital- and patient-level characteristics and the risk of appendiceal rupture and negative appendectomy in children

Initial experience from a double-blind, placebo-controlled, clinical outcome study of ARC1779 in patients with thrombotic thrombocytopenic purpura

Evidence of persistent neurologic injury following thrombotic thrombocytopenic purpura

The aptamer ARC1779 blocks von Willebrand factor-dependent platelet function in patients with thrombotic thrombocytopenic purpura ex vivo

The aptamer ARC1779 is a potent and specific inhibitor of von willebrand factor mediated ex vivo platelet function in acute myocardial infarction

Suchergebnisse filtern